ArticleAmerican journal of cancer research2025
FOXK1-induced upregulation of NXPH4 predicts poor prognosis and promotes hepatocellular carcinoma progression via PI3K/Akt pathway.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neurexophilin 4 facilitates the malignant progression of kidney renal clear cell carcinoma by regulating PI3K/AKT-mediated glycolysis.Molecular genetics and genomics : MGG · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) stands out as a remarkably diverse and complex disease, presenting a myriad of challenges when it comes to predicting prognostic outcomes. Although lactate and branched-chain amino acids (BCAA) are important for the development and progression of various tumors, their function in HCC progression remained largely unclear. The study aimed to identify molecular subtypes in HCC based on lactate metabolism and BCAA metabolism. Clustering 370 HCC patients revealed two distinctive subtypes associated with unfavorable prognosis. Differential expression analysis identified 941 DEGs in lactate metabolism subtypes and 518 in BCAA metabolism subtypes, primarily linked to tumor and metabolism pathways. Prognostic analysis identified 27 LRG-BCAA-DGEs inversely correlated with long-term survival across various cancers. Methylation analysis showed a negative correlation between methylation and mRNA expression of these genes, with limited impact on survival outcomes. NXPH4, dysregulated across tumors, exhibited complex associations with immune cells and prognostic implications in HCC. Functional analysis revealed DEGs associated with endodermal cell differentiation and metabolic pathways. NXPH4 knockdown suppressed HCC cell proliferation, migration, and invasion, indicating its potential as a therapeutic target. Additionally, NXPH4 modulated glucose metabolism via the PI3K/Akt pathway. FOXK1 was identified as a potential transcriptional regulator of NXPH4, suggesting a regulatory axis in HCC tumorigenesis. The study highlights the molecular complexity of HCC, providing insights into potential biomarkers and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.